evobrutinib

a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo

Also Known As:

1-(4-(((6-Amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one; 2-propen-1-one, 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-

Networked: 20 relevant articles (3 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - evobrutinib: 20
  - Piperidines: 17
    - evobrutinib: 20

Experts

1.	Bender, Andrew T: 3 articles (01/2020 - 01/2019)
2.	Grenningloh, Roland: 3 articles (01/2020 - 01/2019)
3.	Siess, Wolfgang: 2 articles (03/2021 - 12/2019)
4.	von Hundelshausen, Philipp: 2 articles (03/2021 - 12/2019)
5.	Martin, Emily C: 2 articles (01/2020 - 01/2019)
6.	Camps, Montserrat: 2 articles (12/2019 - 01/2019)
7.	Head, Jared: 2 articles (12/2019 - 01/2019)
8.	Liu-Bujalski, Lesley: 2 articles (12/2019 - 01/2019)
9.	Morandi, Federica: 2 articles (12/2019 - 01/2019)
10.	Nguyen, Ngan: 2 articles (12/2019 - 01/2019)

Related Diseases

1.	Multiple Sclerosis 12/01/2022 - "Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study." 12/01/2022 - "The pharmacometric analysis of the double-blind, randomized, phase II study (NCT02975349) investigating the safety and efficacy of evobrutinib, explored exposure-response relationships and suitable dosing regimens of evobrutinib for relapsing multiple sclerosis. " 08/01/2023 - "A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis." 01/01/2020 - "Evobrutinib reduced MRI activity in a phase 2 trial, and a phase 3 trial is underway, in patients with relapsing multiple sclerosis. " 01/01/2019 - "Phase II trial of evobrutinib in multiple sclerosis."
2.	Autoimmune Diseases (Autoimmune Disease) 01/01/2020 - "Evobrutinib is, therefore, suitable for investigation in autoimmune diseases." 01/01/2019 - "Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models." 01/01/2019 - "Evobrutinib is a highly selective inhibitor of Bruton's tyrosine kinase (BTK) which may be clinically effective in treating certain autoimmune diseases. " 12/01/2019 - "Clinical investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus." 09/10/2023 - "Evobrutinib is a second-generation, highly selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy in the autoimmune diseases arthritis and multiple sclerosis. "
3.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/01/2023 - "The objective of this phase II, multicenter, randomized, double-blind, placebo-controlled trial was to evaluate the efficacy and safety of evobrutinib in patients with active autoantibody-positive systemic lupus erythematosus (SLE). " 01/01/2023 - "Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial." 08/01/2023 - "The safety data from all three clinical studies are encouraging and can be used to inform further research into using evobrutinib in MS. Clinical Trial Registration: NCT02975349 (multiple sclerosis), NCT03233230 (rheumatoid arthritis), NCT02975336 (systemic lupus erythematosus) (ClinicalTrials.gov)." 01/01/2023 - "Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis." 12/01/2019 - "Clinical investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus."
4.	Rheumatoid Arthritis 08/01/2023 - "The safety data from all three clinical studies are encouraging and can be used to inform further research into using evobrutinib in MS. Clinical Trial Registration: NCT02975349 (multiple sclerosis), NCT03233230 (rheumatoid arthritis), NCT02975336 (systemic lupus erythematosus) (ClinicalTrials.gov)." 01/01/2023 - "Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis." 12/01/2019 - "Clinical investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus." 01/01/2023 - "Analyse the integrated safety profile of evobrutinib, a Bruton's tyrosine kinase inhibitor (BTKi), using pooled data from multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) trials. " 01/01/2021 - "However, an increasing number of trials instead addresses autoimmunity and inflammation in multiple sclerosis, rheumatoid arthritis, pemphigus and systemic lupus erythematosus with the use of either irreversibly binding inhibitors, e.g., evobrutinib and tolebrutinib, or reversibly binding inhibitors, like fenebrutinib. "
5.	Infections 09/10/2023 - "In preliminary PET/CT studies, [11 C]evobrutinib failed to visualize either SARS-CoV-2 pseudovirus infection or LPS-induced injury in mouse models. " 01/01/2023 - "The serious infections EAIR was 2.7 and 2.1 events/100 pt-years for evobrutinib and placebo. " 01/01/2023 - "All doses of evobrutinib were well tolerated, and there was no clear dose effect on the incidence of reported TEAEs, or serious TEAEs, including severe infections. "

Related Drugs and Biologics

1.	Agammaglobulinaemia Tyrosine Kinase
2.	fenebrutinib
3.	Autoantibodies
4.	Dimethyl Fumarate
5.	ibrutinib
6.	zanubrutinib
7.	tirabrutinib
8.	acalabrutinib
9.	Matrix Metalloproteinases (MMPs)
10.	Tyrosine (L-Tyrosine)